Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II intradermal AG0302-COVID19 vaccine study in healthy adults
jRCT2051200085Phase 2Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Nov 2020
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AG0302 in coronavirus disease 2019 (COVID-19), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Safety and Immunogenicity. Started Nov 2020; status: completed.
02
Drugs
AG0302
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2051200085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051200085.